Advances in molecular, genetic and immune signatures of gastric cancer: Are we ready to apply them in our patients’ decision making?
Stavros Gkolfinopoulos, Demetris Papamichael, Panos Papanastasopoulos, Panteleimon Kountourakis, Department of Medical Oncology, BOC Oncology Center, Nicosia 2006, Cyprus
Konstantinos Papadimitriou, Department of Medical Oncology, University Hospital of Antwerp, Antwerp 2650, Belgium
Vassilios Vassiliou, Department of Radiation Oncology, BOC Oncology Center, Nicosia 2006, Cyprus
Author contributions: Gkolfinopoulos S and Papamichael D participated in manuscript preparation and revision, approval of the final version; Papadimitriou K and Papanastasopoulos P participated in manuscript preparation, approval of the final version; Vassiliou V participated in manuscript preparation; Kountourakis P participated in conception and design of the review, manuscript preparation and revision, approval of the final version.
Conflict-of-interest statement: Dr. Kountourakis has nothing to disclose.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Panteleimon Kountourakis, MD, PhD, Attending Doctor, Consultant, Department of Medical Oncology, BOC Oncology Center, 32 Acropoleos Ave, Nicosia 2006, Cyprus. firstname.lastname@example.org
Telephone: +357-22-847402 Fax: +357-22-841388
Received: March 28, 2018
Peer-review started: March 28, 2018
First decision: April 18, 2018
Revised: May 16, 2018
Accepted: June 13, 2018
Article in press: June 14, 2018
Published online: July 15, 2018